Compliance Rate
Compliance Rate
51.23%
Compliant submissions
187
Incompliant submissions
178
Total trials
365
My Organizations' Clinical Trials
Showing 2150 of 2400 entries
View as:
Phase: N/A
Priority: Normal
Start: 07/09/18
End: 08/20/18
Due: 08/20/19
Phase: N/A
Priority: Normal
Start: 02/21/20
End: 05/21/20
Due: 05/21/21
Phase: N/A
Priority: Normal
Start: 07/31/06
End: 08/31/16
Due: 08/31/17
Phase: N/A
Priority: Normal
Start: 10/26/17
End: 09/20/18
Due: 09/20/19
Phase: N/A
Priority: Normal
Start: 07/03/19
End: 03/17/23
Due: 03/17/24
Phase: N/A
Priority: Normal
Start: -
End: 07/31/98
Due: 07/31/99
Phase: N/A
Priority: Normal
Start: 06/30/10
End: 03/31/12
Due: 03/31/13
Phase: N/A
Priority: Normal
Start: 05/30/14
End: 04/30/28
Due: 04/30/29
Phase: N/A
Priority: Normal
Start: 05/22/20
End: 02/24/25
Due: 02/24/26
Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications
Phase: N/A
Priority: Normal
Start: 08/12/22
End: 01/01/27
Due: 01/01/28
Phase: N/A
Priority: Normal
Start: 07/31/04
End: 09/30/06
Due: 09/30/07
Phase: N/A
Priority: Normal
Start: 05/24/07
End: 05/05/14
Due: 05/05/15
Phase: N/A
Priority: Normal
Start: 07/21/15
End: 06/12/18
Due: 06/12/19
Phase: N/A
Priority: Normal
Start: 07/30/18
End: 12/31/29
Due: 12/31/30
Phase: N/A
Priority: Normal
Start: 11/30/97
End: 03/31/03
Due: 03/31/04
Phase: N/A
Priority: Normal
Start: 03/13/06
End: 08/04/06
Due: 08/04/07
Phase: N/A
Priority: Normal
Start: -
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 11/01/09
End: 08/06/18
Due: 08/06/19
Phase: N/A
Priority: Normal
Start: 05/31/16
End: 03/03/21
Due: 03/03/22
Phase: N/A
Priority: Normal
Start: 08/22/17
End: 03/21/23
Due: 03/21/24
Phase: N/A
Priority: Normal
Start: 02/07/07
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 10/31/02
End: 05/31/10
Due: 05/31/11
Phase: N/A
Priority: Normal
Start: 10/31/04
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 10/26/12
End: 08/28/15
Due: 08/28/16
Phase: N/A
Priority: Normal
Start: 08/08/22
End: 03/01/26
Due: 03/01/27